重组人血管内皮抑制素联合顺铂治疗小细胞肺癌的临床分析  

The clinical analysis of small cell lung cancer treatment with recombinant human endostatin injection and cis-platinum complexes

作　　者：代秀丽[1] 董爱红[2] 孙冬梅 

机构地区：[1]滨州市人民医院外科药房,山东省滨州256610 [2]滨州市人民医院家庭病床科,山东省滨州256610 [3]滨州市高新区青田卫生院

出　　处：《中国基层医药》2012年第12期1767-1768,共2页Chinese Journal of Primary Medicine and Pharmacy

摘　　要：目的 探讨重组人血管内皮抑制素联合顺铂治疗小细胞肺癌的临床疗效。方法 选取小细胞肺癌患者共100例,随机分为观察组和对照组,对照组采用顺铂治疗,观察组加用重组人血管内皮抑制素（恩度）治疗。结果 观察组有效率为74.0%,明显高于对照组的60.0%（χ^2=2.16,P〈0.05）;观察组患者的中位生存期11.0个月,明显优于对照组的9.8个月（t=2.02,P〈0.05）;两组不良反应发生情况差异均无统计学意义（P〉0.05）。结论 重组人血管内皮抑制素联合顺铂治疗小细胞肺癌的疗效可靠,未见严重的不良反应,可克服顺铂的耐药性,是一种较好的治疗手段。Objective To explore the clinical effect of small cell lung cancer（SCLC） treatment with recombinant human endostatin injection and cis-platinum complexes.Methods 100 patients with SCLC were divided into 2 groups.The experiment group used cis-platinum complexes while the control group used recombinant human endostatin injection.Results The effective rate of experiment group was obviously higher than the control group（74.0% vs 60.0%,χ2=2.16,P〈0.05）.The median survival time of experiment group was better than control group（t=2.02,P〈0.05）.The diverse of untoward effect of two groups had no difference（P〉0.05）.Conclusion Recombinant human endostatin injection and cis-platinum complexes were better therapy for SCLC,which had stable effect,no severe untoward effect and overcome the drug-fast of cis-platinum complexes.

关 键 词：癌 小细胞 重组人血管内皮抑制素 顺铂 

分 类 号：R734.2[医药卫生—肿瘤]